Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Josep Tabernero, M.D., Ph.D.
Vall d'Hebron University Hospital (HUVH)
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Institut Jules Bordet
Brussels, Belgium
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
- Masarykův Onkologický Ústav
Brno, Czechia
- Institut Gustave Roussy
Paris, France
- Vhio - Vall D'Hebron Institut D'Oncologia
Barcelona, Spain
- Hospital Universitario Hm Sanchinarro
Madrid, Spain
- Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
- Cleveland Clinic Main Campus
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2022
- Primary completion
- 13 Dec 2024
- Completion
- 13 Dec 2024
- Last update posted
- 17 Nov 2025
- Registered enrollment
- 31
- Registry id
- NCT05525286
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.